2-methyl-4-oxo-hexanoic acid | 102539-95-7

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 酮酸及其衍生物
• 英文名称: 2-methyl-4-oxo-hexanoic acid
• 英文别名: 2-methyl-4-oxohexanoic acid；2-Methyl-4-oxo-hexansaeure
• CAS: 102539-95-7
• 化学式: C₇H₁₂O₃
• 分子量: 144.17
• InChiKey: XWNQNPYBBPLMDJ-UHFFFAOYSA-N

物化性质

• 沸点：
  260.2±13.0 °C(Predicted)
• 密度：
  1.058±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  10
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.71
• 拓扑面积：
  54.4
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-methyl-4-oxo-hexanoic acid 在 4-二甲氨基吡啶 、 1-羟基苯并三唑 、 1-(3-二甲基氨基丙基)-3-乙基碳二亚胺 、 间氯过氧苯甲酸 作用下， 以 二氯甲烷 为溶剂， 生成
  参考文献：
  名称：

  Synthesis of a model compound of mappicine ketone based on sulfur-directed 5-exo selective aryl radical cyclization onto enamides

  摘要：

  Enamides 10, upon treatment with Bu3SnH-AIBN, gave 5-exo aryl radical cyclization products 11, which were partially desulfurized to give 1-substituted dihydroisoindoles 7 and 12. This method was applied to the synthesis of a model compound 4 of mappicine ketone (1). (C) 2001 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0040-4039(00)02138-9
• 作为产物：
  描述：

  alkaline earth salt of/the/ methylsulfuric acid 在 盐酸 作用下， 生成 2-methyl-4-oxo-hexanoic acid
  参考文献：
  名称：

  Blaise; Luttringer, Bulletin de la Societe Chimique de France, 1905, vol. <3>33, p. 821

  摘要：

  DOI：

文献信息

• ANTIBODY DRUG CONJUGATES (ADCS) AND ANTIBODY PRODRUG CONJUGATES (APDCS) WITH ENZYMATICALLY CLEAVABLE GROUPS
  申请人：Bayer Pharma Aktiengesellschaft

  公开号：US20180169256A1

  公开（公告）日：2018-06-21

  The present invention relates to novel binder-prodrug conjugates (APDCs) where binders are conjugated with inactive precursor compounds of kinesin spindle protein inhibitors, and to antibody-drug conjugates ADCs and to processes for producing these APDCs and ADCs.

  这项发明涉及新型结合物-前药偶联物（APDCs），其中结合物与动力蛋白纺锤体抑制剂的非活性前体化合物偶联，以及抗体药物偶联物ADCs以及制备这些APDCs和ADCs的方法。
• [EN] 5-[(PIPERAZIN-1-YL)-3-OXO-PROPYL]-IMIDAZOLIDINE-2,4-DIONE DERIVATIVES AS ADAMTS INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS<br/>[FR] DÉRIVÉS 5-[(PIPÉRAZINE-1-YL) -3-OXO-PROPYL]-IMIDAZOLIDINE -2,4-DIONE COMME INHIBITEURS D'ADAMTS POUR LE TRAITEMENT DE L'ARTHROSE
  申请人：GALAPAGOS NV

  公开号：WO2016102347A1

  公开（公告）日：2016-06-30

  The present invention discloses compounds according to Formula (I), wherein R, R2, R3a, R3b, and Cy are as defined herein. The present invention discloses compounds inhibiting ADAMTS, methods for their production, pharmaceutical compositions comprising the same and methods for the prophylaxis and/or treatment of inflammatory conditions and/or diseases involving degradation of cartilage and/or disruption of cartilage homeostasis.

  本发明公开了根据式(I)的化合物，其中R、R2、R3a、R3b和Cy如本文所定义。本发明公开了抑制ADAMTS的化合物、其制备方法、包含该化合物的药物组合物以及用于预防和/或治疗涉及软骨降解和/或软骨稳态破坏的炎症状况和/或疾病的方法。
• [EN] 5-[3-[PIPERAZIN-1-YL]-3-OXO-PROPYL]-IMIDAZOLIDINE-2,4-DIONE DERIVATIVES AS ADAMTS 4 AND 5 INHIBITORS FOR TREATING E.G. OSTEOARTHRITIS<br/>[FR] DÉRIVÉS DE 5-[3-[PIPÉRAZIN-1-YL]-3-OXO-PROPYL]-IMIDAZOLIDINE-2,4-DIONE À UTILISER EN TANT QU'INHIBITEURS D'ADAMTS 4 ET 5 POUR TRAITER PAR EXEMPLE L'ARTHROSE
  申请人：GALAPAGOS NV

  公开号：WO2017211666A1

  公开（公告）日：2017-12-14

  The present invention discloses 5-[3-[piperazin-l-yl]-3-oxo-propyl]-imidazolidine-2,4-dione derivatives according to Formula (I), wherein R1, R2, R3a, R3b, R6a, R6b, the subscript n and Cy are as defined herein. The present invention relates to compounds inhibiting ADAMTS 4 and 5 for the prophylaxis or treatment of inflammatory diseases or diseases involving degradation of cartilage or disruption of cartilage homeostasis, such as e.g. osteoarthritis.

  本发明公开了根据式(I)的5-[3-[哌嗪-1-基]-3-氧代-丙基]-咪唑啉-2,4-二酮衍生物，其中R1、R2、R3a、R3b、R6a、R6b、下标n和Cy如本文所定义。本发明涉及抑制ADAMTS 4和5的化合物，用于预防或治疗炎症性疾病或涉及软骨降解或破坏软骨稳态的疾病，例如骨关节炎。
• [EN] INDOMETHACIN ANALOGS FOR THE TREATMENT OF CASTRATE-RESISTANT PROSTATE CANCER<br/>[FR] ANALOGUES DE L'INDOMÉTACINE DESTINÉS AU TRAITEMENT DU CANCER DE LA PROSTATE RÉSISTANT À LA CASTRATION
  申请人：UNIV VANDERBILT

  公开号：WO2013059245A1

  公开（公告）日：2013-04-25

  Provided are compositions for inhibiting a biological activity of an aldoketo reductase family 1, member C3 (AKR1 C3) polypeptide. In some embodiments, the compositions are indomethacin derivatives that are AKR1 C3-specific inhibitors. Also provided are methods for producing disclosed indomethacin derivatives that substantially lack cyclooxygenase inhibitory activity but that have AKR1C3 inhibitory activity, methods for inhibiting AKR1C3 polypeptide biological activities, and methods for treating prostate tumors in subjects.

  提供了用于抑制醛酮还原酶家族1成员C3（AKR1 C3）多肽的生物活性的组合物。在某些实施例中，这些组合物是吲哚美酸衍生物，是AKR1 C3特异性抑制剂。还提供了生产所述吲哚美酸衍生物的方法，这些衍生物基本缺乏环氧合酶抑制活性，但具有AKR1C3抑制活性，以及抑制AKR1C3多肽生物活性的方法，以及治疗受试者前列腺肿瘤的方法。
• Formation of γ-Oxoacids and 1<i>H</i>-Pyrrol-2(5<i>H</i>)-ones from α,β-Unsaturated Ketones and Ethyl Nitroacetate
  作者：Maialen Aginagalde、Tamara Bello、Carme Masdeu、Yosu Vara、Ana Arrieta、Fernando P. Cossío

  DOI：10.1021/jo101388x

  日期：2010.11.5

  Michael addition of ethyl nitroacetate on α,β-unsaturated ketones followed by Nef oxidation under hydrolytic conditions yields γ-oxoacids instead of the corresponding α,δ-dioxoesters. A concerted decarboxylation step is proposed on the basis of computational results. Finally, conversion of the γ-ketoacids thus prepared into 1H-pyrrol-2(5H)-ones by reaction with primary amines under Paal−Knorr conditions

  在α，β-不饱和酮上迈克尔加成硝基乙酸乙酯，然后在水解条件下进行Nef氧化，生成γ-含氧酸，而不是相应的α，δ-二氧代酯。根据计算结果提出了协同的脱羧步骤。最后，还报道了通过在Paal-Knorr条件下与伯胺反应将如此制备的γ-酮酸转化为1 H-吡咯-2（5 H）-酮。